TORONTO, Feb. 9, 2018 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS or US OTCQX: LHSIF) (the “Company” or “Liberty”) is providing the following statement in response to the Canadian Securities Administration’s (the “CSA”) Staff Notice 51-352 Issuers with U.S. Marijuana-Related Activities (the “Notice”), revised February 8, 2018.
We applaud the CSA for affirming and expanding upon their disclosure-based approach, originally announced in October 2017. This updated response reinforces Liberty’s approach to the U.S. medical cannabis market while reducing the existing uncertainty and allowing for ongoing capital market support.
George Scorsis, Director and CEO of Liberty
We endorse an approach that requires enhanced risk disclosure to inform the capital markets and all stakeholders. We are proud to say that Liberty abides by the requirements and will continue to fulfill all of its obligations under the revised Notice.
Liberty is a licensed medical cannabis company that adheres to the laws in the U.S. states in which it operates. The Company will continue to focus on their aggressive growth plans in the U.S. medical cannabis market. These growth plans will only focus on those states where a robust legal regime exists for medical cannabis. In addition, the Company will also continue to work with their governmental advisors at the U.S. federal level to provide assistance to governmental officials with the ongoing U.S. policy-making initiatives related to medical cannabis in the United States.
Liberty will continue to actively monitor regulatory developments in both the U.S. and Canada and develop strategies to effectively respond on behalf of its stakeholders on a timely basis to any new policy initiatives in both Canada and the United States within the medical cannabis industry.
For more information on Liberty please visit www.libertyhealthsciences.com
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. (“Liberty”) is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
